IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 321 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 1.16 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,631,000 | -0.5% | 58,000 | -10.0% | 0.01% | +9.1% |
Q2 2023 | $2,643,000 | +5.3% | 64,426 | -8.2% | 0.01% | +10.0% |
Q1 2023 | $2,510,000 | -13.0% | 70,219 | -8.0% | 0.01% | -23.1% |
Q4 2022 | $2,884,000 | -14.3% | 76,345 | +0.3% | 0.01% | -13.3% |
Q3 2022 | $3,367,000 | +20.7% | 76,123 | +1.0% | 0.02% | +25.0% |
Q2 2022 | $2,789,000 | -3.1% | 75,343 | -3.0% | 0.01% | +20.0% |
Q1 2022 | $2,877,000 | +11.7% | 77,666 | -8.3% | 0.01% | +11.1% |
Q4 2021 | $2,576,000 | -12.2% | 84,661 | -3.2% | 0.01% | -10.0% |
Q3 2021 | $2,933,000 | -8.1% | 87,444 | +9.2% | 0.01% | -9.1% |
Q2 2021 | $3,193,000 | +2.3% | 80,054 | +15.4% | 0.01% | -8.3% |
Q1 2021 | $3,120,000 | -14.0% | 69,385 | +8.1% | 0.01% | -25.0% |
Q4 2020 | $3,630,000 | +47.7% | 64,194 | +23.9% | 0.02% | +23.1% |
Q3 2020 | $2,458,000 | -16.3% | 51,794 | +4.0% | 0.01% | -23.5% |
Q2 2020 | $2,938,000 | +20.5% | 49,824 | -3.4% | 0.02% | 0.0% |
Q1 2020 | $2,438,000 | -7.9% | 51,572 | +17.7% | 0.02% | +21.4% |
Q4 2019 | $2,648,000 | -18.8% | 43,831 | -19.5% | 0.01% | -17.6% |
Q3 2019 | $3,260,000 | -5.3% | 54,423 | +1.6% | 0.02% | -10.5% |
Q2 2019 | $3,444,000 | -22.9% | 53,591 | -2.6% | 0.02% | -17.4% |
Q1 2019 | $4,468,000 | +96.0% | 55,048 | +30.5% | 0.02% | +76.9% |
Q4 2018 | $2,280,000 | +1.2% | 42,172 | -3.4% | 0.01% | +18.2% |
Q3 2018 | $2,252,000 | +14.5% | 43,670 | -7.5% | 0.01% | +10.0% |
Q2 2018 | $1,967,000 | -8.4% | 47,205 | -3.1% | 0.01% | -9.1% |
Q1 2018 | $2,147,000 | -13.9% | 48,718 | -1.7% | 0.01% | -8.3% |
Q4 2017 | $2,493,000 | -0.6% | 49,569 | +0.2% | 0.01% | -7.7% |
Q3 2017 | $2,508,000 | -51.8% | 49,477 | -51.6% | 0.01% | -7.1% |
Q2 2017 | $5,200,000 | +152.1% | 102,204 | +99.1% | 0.01% | +16.7% |
Q1 2017 | $2,063,000 | -12.0% | 51,323 | 0.0% | 0.01% | -7.7% |
Q4 2016 | $2,344,000 | +27.7% | 51,323 | +2.5% | 0.01% | +18.2% |
Q3 2016 | $1,835,000 | +76.8% | 50,077 | +12.3% | 0.01% | +57.1% |
Q2 2016 | $1,038,000 | -43.3% | 44,584 | -1.4% | 0.01% | -41.7% |
Q1 2016 | $1,831,000 | -23.0% | 45,205 | +17.8% | 0.01% | -20.0% |
Q4 2015 | $2,377,000 | – | 38,376 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |